GoKawiilHims launches testosterone replacement therapy service for men
Hims, the publicly traded telehealth company, has launched a testosterone replacement therapy service for cisgender men, offering two injectable options and an oral pill after an at-home blood test. Peter Stahl, a urologist and senior VP of men's health at Hims, says the company aims to test as many men as possible for testosterone deficiency. Hims began in 2017 selling erectile dysfunction drugs and has since expanded into women's health, now serving 2.9 million customers.
GoKawiil's interpretation of the reporting above, not reported fact.
The launch positions Hims to capture a wave of consumer and cultural interest in testosterone, a topic amplified by podcasters and political figures discussing 'low T.' It also puts Hims in direct competition with numerous telehealth startups already selling testosterone therapy, some of which market it as an anti-aging or lifestyle product rather than treatment for a diagnosed medical condition, which could raise questions about oversight and appropriate use as the market grows.
- Hims now offers injectable and oral testosterone replacement therapy following an at-home blood test.
- The service targets cisgender men and reflects Hims's expansion beyond erectile dysfunction and women's health.
- Hims enters a crowded telehealth market where testosterone is often marketed as a lifestyle or anti-aging product.
Source: wired.com — Kate Knibbs, 2026-10-21
Published there as: “Telehealth Giant Hims Wants to Test Every Dude for Low Testosterone”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.